William Blair & Company
TXG icon

William Blair & Company’s 10x Genomics TXG Stock Holding History

William Blair & Company’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,297
Closed -$789K – 2009
2021
Q4 		$789K Sell
5,297
-2,644
-33% -$405K ﹤0.01% 1040
2021
Q3 		$1.16M Buy
7,941
+100
+1% +$17.2K ﹤0.01% 878
2021
Q2 		$1.53M Buy
7,841
+1,895
+32% +$343K 0.01% 781
2021
Q1 		$1.08M Buy
5,946
+1,551
+35% +$268K ﹤0.01% 872
2020
Q4 		$622K Buy
+4,395
New +$638K ﹤0.01% 1024

Other funds holding TXG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair & Company's TXG Position: Q1 2022 in Review

William Blair & Company sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 5,297 shares — an estimated $789K sold.

William Blair & Company first reported a position in TXG in Q4 2020 and held it in 5 quarters. The position peaked at $1.53M in Q2 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

  • William Blair & Company reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
  • William Blair & Company sold 5,297 10x Genomics shares in Q1 2022, an estimated $789K.
  • William Blair & Company first reported a position in 10x Genomics in Q4 2020 and held it in 5 quarters.
  • William Blair & Company's 10x Genomics position peaked at $1.53M in Q2 2021.
  • 314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on William Blair & Company's 13F filing for Q1 2022, filed 13 May 2022.